These figures have recently been published by beTransparent.be – a platform for transparency in the healthcare sector – and follow a recent publication that indicates how the pharmaceutical industry continues to grow in Belgium.
You are here
Belgium is EU frontrunner in pharma-medical collaborations
A whopping EUR 2.89 billion: that’s how much the 77 most innovative pharmaceutical companies funneled into research and development in Belgium in 2016. A large part of this amount went to collaborations with the medical community, making Belgium the European leader in this regard.
Of the total investment amount of EUR 2.89 billion, the 77 most innovative pharmaceutical companies in Belgium channeled around EUR 148.3 million into collaborations with health and care organizations, including universities, university hospitals as well as associations for doctors and pharmacists. What’s more, these investments confirm that Belgium is in pole position in Europe when it comes to pharma-medical collaborations.
The lion’s share of these investments (67%) went to joint R&D initiatives such as clinical studies, representing a sum of EUR 99.2 million. Furthermore, 16% was channeled into scientific gatherings, 12% (EUR 17.3 million) went to allowances and donations, and 6% was used to pay for consultancy assignments and services.
Close-knit collaborations between the pharmaceutical and the medical communities enable both industries to drive the development process of new medicines for the benefit of patients. As such, frequent interaction and information exchange between both parties are crucial to optimizing care trajectories.
With Dutch as its official language, Flanders (Dutch: Vlaanderen) is the northern region of Belgium. The capital of both Belgium and Flanders is Brussels.